Tumor necrosis factor-α promoter polymorphism at position-308 predicts response to combination therapy in hepatitis C virus infection
Tumor necrosis factor-α promoter polymorphism at position-308 predicts response to combination therapy in hepatitis C virus infection
复制标题
DOI：
10.1086/498244
复制
发表时间：
2006-01-01
影响因子：
6.4
通讯作者：
Yu, ML
中科院分区：
文献类型：
--
作者：
Dai, CY;Chuang, WL;Yu, ML
对141例慢性丙型肝炎病毒（HCV）感染者肿瘤坏死因子（TNF）α启动子区-308（TNF 308.2）和-238（TNF 238.2）位G → A转换进行了检测。患者接受大剂量干扰素（IFN）-α和病毒唑联合治疗24周。共有100例患者（70.9%）在治疗后出现持续病毒学应答（SVR）。TNF 308.2等位基因与SVR独立相关，特别是在HCV基因型1b感染和血清HCV RNA> 200，000 IU/mL的患者中。总之，对高剂量IFN-α和利巴韦林联合治疗的反应可能至少部分与宿主遗传因素有关。
The G -> A transition in the tumor necrosis factor (TNF) a promoter region at position -308 (TNF308.2) and -238 (TNF238.2) were determined in 141 patients with chronic hepatitis C virus (HCV) infection. Patients received combination therapy with high-dose interferon (IFN)-alpha and ribavirin for 24 weeks. A total of 100 patients (70.9%) had a sustained virologic response (SVR) after treatment. The TNF308.2 allele was independently associated with an SVR, particularly in patients with HCV genotype 1b infection and > 200,000 IU of HCV RNA/mL in serum. In conclusion, the response to combination therapy with high-dose IFN-alpha and ribavirin may be associated, at least in part, with host genetic factors.